Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients

Kenneth A. Lichtenstein, Kathleen M. Delaney, Carl Armon, Douglas J. Ward, Anne C. Moorman, Kathleen C. Wood, Scott D. Holmberg, Tony Tong, Rose K. Baker, Frank J. Palella, Joan S. Chmiel, Maria Deloria Knoll, Barbara Gillespie, Erin Nekervis, Kenneth S. Greenberg, Benjamin Young, Barbara Wideck, Cheryl Stewart, Peggy Zellner, Bienvenido G. YangcoKalliope Halkias, Cheryl Lapierre, Charles A. Owen, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M. Tedaldi, Linda Walker-Kornegay, Joseph B. Marszouk, Roger T. Phelps, Mark Rachel, Robert E. McCabe, Richard M. Novak, Jonathan P. Uy, Andrea Wendrow

Research output: Contribution to journalArticle

Abstract

To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1%) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95% CI: 1.9-17.1; p = .003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95% CI: 1.3-13.1; p = .013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95% CI: 1.1-5.4; p = .024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy.

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume32
Issue number1
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

HIV-1
Fats
Incidence
Multivariate Analysis
HIV
Anti-Retroviral Agents
T-Lymphocytes
Lymphocyte Count
CD4 Lymphocyte Count
HIV Infections
Body Mass Index
Outpatients
Cell Count
Pharmaceutical Preparations
Surveys and Questionnaires
Therapeutics

Keywords

  • Antiretroviral agent
  • Lipoatrophy
  • Lipodystrophy

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Lichtenstein, K. A., Delaney, K. M., Armon, C., Ward, D. J., Moorman, A. C., Wood, K. C., ... Wendrow, A. (2003). Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 32(1), 48-56.

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. / Lichtenstein, Kenneth A.; Delaney, Kathleen M.; Armon, Carl; Ward, Douglas J.; Moorman, Anne C.; Wood, Kathleen C.; Holmberg, Scott D.; Tong, Tony; Baker, Rose K.; Palella, Frank J.; Chmiel, Joan S.; Knoll, Maria Deloria; Gillespie, Barbara; Nekervis, Erin; Greenberg, Kenneth S.; Young, Benjamin; Wideck, Barbara; Stewart, Cheryl; Zellner, Peggy; Yangco, Bienvenido G.; Halkias, Kalliope; Lapierre, Cheryl; Owen, Charles A.; Fuhrer, Jack; Ording-Bauer, Linda; Kelly, Rita; Esteves, Jane; Tedaldi, Ellen M.; Walker-Kornegay, Linda; Marszouk, Joseph B.; Phelps, Roger T.; Rachel, Mark; McCabe, Robert E.; Novak, Richard M.; Uy, Jonathan P.; Wendrow, Andrea.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 1, 01.2003, p. 48-56.

Research output: Contribution to journalArticle

Lichtenstein, KA, Delaney, KM, Armon, C, Ward, DJ, Moorman, AC, Wood, KC, Holmberg, SD, Tong, T, Baker, RK, Palella, FJ, Chmiel, JS, Knoll, MD, Gillespie, B, Nekervis, E, Greenberg, KS, Young, B, Wideck, B, Stewart, C, Zellner, P, Yangco, BG, Halkias, K, Lapierre, C, Owen, CA, Fuhrer, J, Ording-Bauer, L, Kelly, R, Esteves, J, Tedaldi, EM, Walker-Kornegay, L, Marszouk, JB, Phelps, RT, Rachel, M, McCabe, RE, Novak, RM, Uy, JP & Wendrow, A 2003, 'Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients', Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 1, pp. 48-56.
Lichtenstein, Kenneth A. ; Delaney, Kathleen M. ; Armon, Carl ; Ward, Douglas J. ; Moorman, Anne C. ; Wood, Kathleen C. ; Holmberg, Scott D. ; Tong, Tony ; Baker, Rose K. ; Palella, Frank J. ; Chmiel, Joan S. ; Knoll, Maria Deloria ; Gillespie, Barbara ; Nekervis, Erin ; Greenberg, Kenneth S. ; Young, Benjamin ; Wideck, Barbara ; Stewart, Cheryl ; Zellner, Peggy ; Yangco, Bienvenido G. ; Halkias, Kalliope ; Lapierre, Cheryl ; Owen, Charles A. ; Fuhrer, Jack ; Ording-Bauer, Linda ; Kelly, Rita ; Esteves, Jane ; Tedaldi, Ellen M. ; Walker-Kornegay, Linda ; Marszouk, Joseph B. ; Phelps, Roger T. ; Rachel, Mark ; McCabe, Robert E. ; Novak, Richard M. ; Uy, Jonathan P. ; Wendrow, Andrea. / Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 32, No. 1. pp. 48-56.
@article{9c8e191664ed44bfad6674207beb88b3,
title = "Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients",
abstract = "To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1{\%}) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95{\%} CI: 1.9-17.1; p = .003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95{\%} CI: 1.3-13.1; p = .013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95{\%} CI: 1.1-5.4; p = .024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy.",
keywords = "Antiretroviral agent, Lipoatrophy, Lipodystrophy",
author = "Lichtenstein, {Kenneth A.} and Delaney, {Kathleen M.} and Carl Armon and Ward, {Douglas J.} and Moorman, {Anne C.} and Wood, {Kathleen C.} and Holmberg, {Scott D.} and Tony Tong and Baker, {Rose K.} and Palella, {Frank J.} and Chmiel, {Joan S.} and Knoll, {Maria Deloria} and Barbara Gillespie and Erin Nekervis and Greenberg, {Kenneth S.} and Benjamin Young and Barbara Wideck and Cheryl Stewart and Peggy Zellner and Yangco, {Bienvenido G.} and Kalliope Halkias and Cheryl Lapierre and Owen, {Charles A.} and Jack Fuhrer and Linda Ording-Bauer and Rita Kelly and Jane Esteves and Tedaldi, {Ellen M.} and Linda Walker-Kornegay and Marszouk, {Joseph B.} and Phelps, {Roger T.} and Mark Rachel and McCabe, {Robert E.} and Novak, {Richard M.} and Uy, {Jonathan P.} and Andrea Wendrow",
year = "2003",
month = "1",
language = "English (US)",
volume = "32",
pages = "48--56",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients

AU - Lichtenstein, Kenneth A.

AU - Delaney, Kathleen M.

AU - Armon, Carl

AU - Ward, Douglas J.

AU - Moorman, Anne C.

AU - Wood, Kathleen C.

AU - Holmberg, Scott D.

AU - Tong, Tony

AU - Baker, Rose K.

AU - Palella, Frank J.

AU - Chmiel, Joan S.

AU - Knoll, Maria Deloria

AU - Gillespie, Barbara

AU - Nekervis, Erin

AU - Greenberg, Kenneth S.

AU - Young, Benjamin

AU - Wideck, Barbara

AU - Stewart, Cheryl

AU - Zellner, Peggy

AU - Yangco, Bienvenido G.

AU - Halkias, Kalliope

AU - Lapierre, Cheryl

AU - Owen, Charles A.

AU - Fuhrer, Jack

AU - Ording-Bauer, Linda

AU - Kelly, Rita

AU - Esteves, Jane

AU - Tedaldi, Ellen M.

AU - Walker-Kornegay, Linda

AU - Marszouk, Joseph B.

AU - Phelps, Roger T.

AU - Rachel, Mark

AU - McCabe, Robert E.

AU - Novak, Richard M.

AU - Uy, Jonathan P.

AU - Wendrow, Andrea

PY - 2003/1

Y1 - 2003/1

N2 - To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1%) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95% CI: 1.9-17.1; p = .003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95% CI: 1.3-13.1; p = .013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95% CI: 1.1-5.4; p = .024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy.

AB - To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1%) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95% CI: 1.9-17.1; p = .003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95% CI: 1.3-13.1; p = .013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95% CI: 1.1-5.4; p = .024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy.

KW - Antiretroviral agent

KW - Lipoatrophy

KW - Lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=0037233820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037233820&partnerID=8YFLogxK

M3 - Article

C2 - 12514413

AN - SCOPUS:0037233820

VL - 32

SP - 48

EP - 56

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -